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Recombinant proteinsDisorders of the central nervous system (CNS), including stroke, neurodegenerative diseases, and brain tumors,
are the world’s leading causes of disability. Delivery of drugs to the CNS is complicated by the blood–brain
barriers that protect the brain from the unregulated leakage and entry of substances, including proteins, from
the blood. Yet proteins represent one of the most promising classes of therapeutics for the treatment of CNS
diseases. Many strategies for overcoming these obstacles are in development, but the relatively straightforward
approach of bypassing these barriers through direct intrathecal administration has been largely overlooked.
Originally discounted because of its lack of usefulness for delivering small, lipid-soluble drugs to the brain, the
intrathecal route has emerged as a useful, in some cases perhaps the ideal, route of administration for certain
therapeutic protein and targeted disease combinations. Here, we review blood–brain barrier functions and cere-
brospinalﬂuid dynamics and their relevance to drug delivery via the intrathecal route, discuss animal and human
studies that have investigated intrathecal delivery of protein therapeutics, and outline several characteristics of
protein therapeutics that can allow them to be successfully delivered intrathecally.
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-NC-ND license.1. Introduction
The World Health Organization has called neurological disorders
one of the greatest threats to public health, making their treatment a
critical unmet need in the current healthcare environment (World
Health Organization, 2006). It is estimated that over 1 billion people
worldwide suffer from a neurological disorder, including brain tumors,
epilepsy, cerebrovascular diseases, neurodegenerative disorders, de-
pression, multiple sclerosis, autoimmune encephalopathy, and chronic
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Effective treatment of most of these and other neurological conditions
may require the use of drugs with sites of action within the central
nervous system (CNS). However, the blood–brain barrier (BBB), a protec-
tor of the CNS and a major regulator of its environment, impedes the
blood-to-brain entry of most potential therapeutics.
Strategies under investigation to overcome the problem of the BBB
can be roughly divided into two broad categories. The ﬁrst category
comprises techniques that allow or facilitate the crossing of drugs
through the BBB (e.g. molecular Trojan horses, proton-coupled
oligopeptide transporters, exosomes, liposomes, nanoparticles, chimeric
peptides, prodrugs), while the second category consists of techniques
that bypass the BBB altogether via direct delivery to the CNS (Smith
et al., 2004; Alam et al., 2010; Tan et al., 2010; Guo et al., 2012; Vlieghe
& Khrestchatisky, 2013). In the second category, several techniques
have been investigated, including BBB disruption, and intrathecal (IT),
intracerebroventricular (ICV), and intranasal delivery. This review focus-
es speciﬁcally on IT delivery. Because promising reports for ICV and in-
tranasal delivery and BBB disruption have been extensively described
(Alam et al., 2010; Rajadhyaksha et al., 2011; Tayebati et al., 2013;
Zhao et al., 2013), we will not recapitulate them here. Instead, this
review is intended to re-examine the potential of IT drug delivery to
allow penetration of protein therapeutics to the brain parenchyma, a
role that has been largely discounted in the past.We beginwith a discus-
sion of endogenous BBBmechanisms and CNS ﬂuid ﬂow dynamics, then
examine current data demonstrating effective IT delivery of particular
classes of therapeutic proteins to the brain. We conclude with a consid-
eration of ideal molecules for IT delivery and promising future applica-
tions of this technology.
2. Barriers to the delivery of drugs
to the brain and cerebrospinal ﬂuid
Drug delivery to the CNS is complicated by complex biological bar-
riers generally termed the blood–brain barriers, including the vascular
blood–brain barrier (BBB), blood–cerebrospinal ﬂuid barrier, and spe-
cialty barriers such as the blood–retinal barrier (Neuwelt et al., 2008).
These barriers serve many functions for their dependent tissue beds.
The most widely known function, especially for the vascular BBB, is
the prevention of the unregulated movement of substances from the
blood into the CNS. Generating and maintaining stable resting poten-
tials, action potentials, and synaptic transmission, together with the
massive spatial and temporal summation of nerve impulses necessary
for CNS function, requires an extreme degree of control over ionic,
protein, and neurotransmitter concentrations in CNS ﬂuids. The BBB
thus affects and even regulates many of the complex interactions be-
tween the peripheral tissues and the CNS that are mediated through the
blood stream, including neuroimmune interactions (Quan & Banks,
2007), feeding and energy balance (Banks, 2008), and even those affect-
ing cognition (Banks, 2012).
The simplest mechanism by which molecules can cross the BBB is
passive transmembrane diffusion. The degree to which a substance
can enter by thismechanism is dictated by its lipid solubility andmolec-
ular weight, with small, lipid-soluble substances crossing more efﬁ-
ciently than large, hydrophilic substances. Steroid hormones are good
examples of endogenous substances that can cross the BBB in this
manner (Banks, 2012). Most small molecule recreational drugs also
cross the BBB by this mechanism, including morphine, heroine, and
ethanol (Becker & Greig, 2010). Exploitation of passive transmembrane
diffusion in drug delivery has been hampered, however, by the presence
of CNS-to-blood (efﬂux) saturable transport systems (Begley, 2004).
Efﬂux transporters at the BBB serve critical functions, controlling elec-
trolyte levels and limiting CNS exposure to endogenous and exogenous
neurotoxins and to other endogenous biologics, including enkephalins
and immunoglobulin G molecules, but they complicate the delivery of
potential protein therapeutics to the CNS (Begley, 2004; Banks, 2005).We have shown, for example, that efﬂux of the neurotrophic peptide,
pituitary adenylate cyclase-activating polypeptide 27, limits it accumula-
tion in the brain and that inhibition of the efﬂux transporter allows intra-
venously administered peptide to accumulate in the brain to therapeutic
levels (Dogrukol-Ak et al., 2009).
Inﬂux transporters are also located at the BBB in large numbers, in-
cluding those for glucose, amino acids, organic acids, vitamins,minerals,
electrolytes, nucleic acids, peptides, feeding hormones, immune cells,
and cytokines (Oldendorf, 1971; Davson & Segal, 1996; Engelhardt,
2008). Use of an inﬂux transporter by a substance can increase its
brain uptake to 4- to 30-fold over what would be predicted from entry
via a passive transmembrane route (Oldendorf, 1971). A few drugs are
known to use endogenous, saturable inﬂux transport systems to enter
the CNS, including L-dopa, donepezil, valproic acid, and gabapentin
(Pardridge, 2007). Utilizing inﬂux transporters for drug delivery of
proteins is fraught with its own special difﬁculties, however. For exam-
ple, the proteins which transport certain ligands across the BBB are not
always the same proteins which act as receptors within the CNS (Pan &
Kastin, 1999). As such, a modiﬁcation that enhances transport of an
endogenous ligand across the BBB can also have the unwanted effect
of reducing its binding afﬁnity to its CNS receptor. Further, recombinant
proteins are unpredictably sensitive to being modiﬁed. Encapsulation,
alteration to the base sequence (fusion proteins), and slight changes
to glycosylation patterns can cause recombinant proteins to fold im-
properly, lose stability, lose enzymatic activity, or become more immu-
nogenic (Jorgensen et al., 2006; Jorgensen & Nielson, 2009; Tan et al.,
2010).
Many drug delivery techniques are in development with the aim of
facilitating BBB crossing, as mentioned above, although a full discussion
of these is outside the scope of this review. A different strategy is direct
injection of protein therapeutics into the cerebrospinal ﬂuid (CSF)
in order to bypass the BBB altogether (Patel et al., 2009; Alam et al.,
2010; Rajadhyaksha et al., 2011). Administration into CSF is accom-
plished by injection into the lateral ventricles of the brain (ICV adminis-
tration), the subarachnoid space at the level of the cisterna magna, or
the lumbar spine (IT administration). Direct CNS administrations have
been successfully employed in instances where a local effect of the
delivered therapeutic is desired, such as in painmanagement, treatment
of spasticity, and cancer chemotherapy. A larger extent of penetration
beyond the site of injection,which is needed to treat neurodegenerative
disease, is inﬂuenced primarily by the ﬂow dynamics of the CSF.
3. Cerebrospinal and interstitial ﬂuid ﬂow
and dynamics: Implications for drug delivery
A thorough understanding of the ﬂuid ﬂow dynamics in the brain is
critical when considering the distribution patterns for protein drugs
administered directly into the CNS. In the body, interstitial ﬂuid (ISF),
containing sugars, salts, lipids, amino acids, coenzymes, hormones,
and cellular waste products, bathes nearly every cell, including those
of the brain. ISF ﬂow plays a key role in nutrient and waste transporta-
tion, intercellular signaling, immune regulation, and themaintenance of
cellular homeostasis throughout the body. The regulation of both colloi-
dal osmotic pressure and ﬂuid volume is dependent upon this efﬁcient
removal of soluble proteins and waste products from the ISF (Scallan
et al., 2010; Wiig & Swartz, 2012).
Within the brain ventricles, a second CNS ﬂuid, the CSF, is continu-
ously produced. The major direction of CSF ﬂow is between the sites of
production in the choroid plexuses (Johanson, 1988) and the major
sites of reabsorption in the arachnoid villi and in the primitive lymphatic
system located at the cribriform plate (Knopf et al., 1995; Boulton et al.,
1999). The total volume of human CSF is about 150 mL, and the human
brain produces approximately 500 mL of CSF per day (Johanson et al.,
2008). It has been calculated that while the ISF is replaced relatively
slowly (every 20 hours), the rate of turnover of CSF is faster and depen-
dent on the size of the brain, with the mouse turning over its CSF
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& Patlak, 1992; Davson & Segal, 1996; Begley et al., 2000; Johanson
et al., 2008; Begley, 2012).
Although somatic ISF drains into lymphatic vessels, such vessels are
notably lacking in the CNS, despite the fact that the intense metabolic
activity of neural tissue and its exquisite sensitivity to changes in the ex-
tracellular environment would seem to demand an efﬁcient lymphatic
vasculature. The absence of such vasculature led to early work whereby
the role of CSF, which ﬂows throughout the ventricular system in the
CNS, was clariﬁed as critical to ISF solute clearance from the brain via
paravascular pathways (Rennels et al., 1990, 1985). Recent elegant
experiments in mice have expanded our understanding of CNS ﬂuid
ﬂow, with resulting implications for drug delivery (Begley, 2012; Iliff
et al., 2012). Iliff and colleagues investigated the ﬂow of CSF into and
through the brain interstitium through a series of ex vivo and in vivo ex-
periments in mice using ﬂuorescent tracers of different molecular
weights. In the ﬁrst set of experiments, tracers of three different molec-
ular weights (759 Da, 3 kDa, and 2000 kDa)were infused into subarach-
noid space of anesthetized mice, from which point they entered the
brain along paravascular spaces (Iliff et al., 2012). The large 2000 kDa
tracer was conﬁned to the paravascular spaces and did not enter the in-
terstitial space, but the 3 kDa tracer entered the interstitium from the
paravascular space and from the pial surface. The smallest tracer of
759 Da rapidly disseminated throughout the interstitial spaces of the
brain, leaving only a small amount in the paravascular spaces through
which it had entered. Building upon these ﬁndings, the investigators
used two-photon laser scanning microscopy through a closed cranial
window in anesthetized mice to conduct real-time imaging of the
movement of the same 3 kDa and 2000 kDa tracers after intracisternal
injection (Iliff et al., 2012). After injection, both of the tracers rapidly
entered the brain along the outside of cortical surface arteries and
penetrating arterioles. Movement from the paravascular spaces into
the interstitium occurred readily for the 3 kDa tracer, but the 2000
kDa tracer remained conﬁned to the paravascular space. Themovement
of the 3 kDa tracer into the interstitium was dependent on the
aquaporin-4 water channel localized in perivascular astrocytic endfeet,
and its movement was abolished in Aqp4-null mice.
Ex vivo techniqueswere then used tomap the exit pathway from the
brain of a 45 kDa tracer after intracisternal injection. After injection, the
45 kDa tracer moved rapidly inward along penetrating arteries and
arterioles to reach the terminal capillary beds throughout the brain. The
largest inﬂuxes were seen along large ventral perforating arteries of the
basal ganglia and thalamus. Exit from the brain appeared to occur along
both the medial internal cerebral veins and the lateral-ventral caudal
rhinal veins. Interestingly, tracer injected intraparenchymally into the
cortex, striatum, or thalamus was cleared along the same pathways.
The authors concluded that the ISF and CSF moving through the brain
parenchyma share the same paravenous drainage pathways. Because
the brain-wide ﬂuid transport that the authors observed in their series
of experiments is dependent upon astroglial water ﬂux, and because it
serves a lymphatic-like function in clearing solutes from the interstitial
space, the authors coined the term “glymphatic pathway” to describe
their ﬁndings (Iliff et al., 2012). This glymphatic pathway may help IT-
administered substances that reach the subarachnoid CSF to distribute
more deeply into the brain than would be predicted were penetration
to depend on diffusion only.
4. Direct delivery of protein therapeutics to the CNS
Early human studies of proteins administered by the ICV route found
that they were rapidly cleared from the CSF and brain into the blood,
presumably failing to penetrate deeply into the brain parenchyma
(Greene et al., 1969; Ghersi-Egea et al., 1996). Some later studies were
similarly disappointing. For example, glial cell line-derived neurotroph-
ic factor, a peptide that promotes survival of dopamine neurons, failed
to produce any improvements in Uniﬁed Parkinson’s Disease RatingScale scores when delivered into the ventricles of patients with ad-
vanced Parkinson’s disease by an implanted catheter and access port
(Nutt et al., 2003). A later animal study investigating insulin-like growth
factor-1 for its potential neuroprotective effects in an Alzheimer’s
disease model was no more encouraging. After unilateral ICV injection
in the ratmodel, nearly all of the insulin-like growth factor-1was cleared
from the brain by 1 hour after injection, and very little penetrated into
the parenchyma (Nagaraja et al., 2005).
Despite these well-known disappointing results, studies have docu-
mented successful ICV or IT delivery of large protein therapeutics to the
brain parenchyma. One of the ﬁrst examples of successful delivery in an
animal model was with leptin, which after lumbar IT administration
into the CSF of baboons and dogswas shown to reach the hypothalamus
and so inﬂuence feeding (LeBel et al., 1999; McCarthy et al., 2002). This
early work rekindled the interest in direct CNS administration of bio-
logics, which has since been shown in animal studies to be a potentially
viable therapeutic approach in several diseases, as discussed below.
4.1. IT Nogo-A Antibodies for Stroke
One factor affecting functional recovery after stroke is the neurite-
outgrowth inhibitory environment present in the adult CNS. Proteins
such as Nogo-A appear to prevent ﬁber regeneration, sprouting, and
new network formation, contributing to the failure of CNS axons to
regrow and reconnect after injury (Pernet & Schwab, 2012). IT-
administered anti–Nogo-A antibody has been shown to penetrate into
the corpus callosum and the striatal white matter in rat models and
has resulted in improvements in measures of functional recovery (Tsai
et al., 2007). In a stroke model, macaque monkeys implanted with
osmotic pumps delivering anti–Nogo-A antibody to the IT and subdural
spaces showed recovery on the Brinkmanbox task, which tests reaching
and grasping. Recovery ranged from 73% to 89.6% of pre-lesion levels in
treated animals, compared with below 50% recovery in the control
animals (Hamadjida et al., 2012). The treated animals, but not controls,
also exhibited an enhanced callosal connectivity with the ipsilesional
premotor cortex, based on normalized numbers of retrogradely labeled
neurons in the intact hemisphere.
4.2. IT enzyme replacement for neuropathic lysosomal storage diseases
The lysosomal storage diseases are inherited disorders characterized
by a deﬁciency in one or more speciﬁc lysosomal enzymes, resulting in
the accumulation of undigested or partially digested macromolecules
within cells and tissues (Winchester et al., 2000). Of the approximately
50 lysosomal storage diseases, two-thirds manifest neurological and
cognitive declines (Hemsley & Hopwood, 2009). Peripheral administra-
tion of the missing enzyme can result in recovery of the peripheral
tissues, but it does little to reverse CNS manifestations of the disease.
Studies in animal models of several neuropathic lysosomal storage
disorders have demonstrated that IT or ICV administration of the miss-
ing enzyme is feasible and potentially effective. Rodent studies are sum-
marized in Table 1. In general, these studies have found penetration of
recombinant enzyme into the brain parenchyma; in some cases locali-
zation to the lysosomes of neuronal cells has been veriﬁed via co-
immunostaining with lysosomal-associated membrane protein 2 and
neuronal nuclear antigen. Signiﬁcant reduction or normalization of
storage material levels in the brain as well as improvements in lifespan
or cognitive performance testing have also been seen. Probably of great
signiﬁcance for the IT administration of lysosomal enzymes is the phe-
nomenon of cell uptake of the recombinant proteins by neurons and
glia, mediated by mannose-6-phosphate receptors or other uptake
mechanisms (Calias et al., 2012), thus effectively rescuing them from
the extracellular ﬂuid and CSF and reducing the extent of clearance by
bulk ﬂow.
Large animal studies of brain delivery of recombinant enzymes
have been conducted for several lysosomal diseases, including
Table 1
Studies of intracerebroventricular (ICV) and intrathecal (IT) administration of recombinant enzymes in rodent models of lysosomal storage diseases.
Study Disease Organism Protein Delivery Findings in Treated Animals
Cabrera-Salazar
et al. 2010
Gaucher disease Mouse Glucocerebrosidase Bilateral ICV injection Enzyme detected in parenchyma. Signiﬁcant reduction
in storage material. Lifespan increased by about 50%.
Lee et al., 2007 Globoid cell
leukodystrophy
(Krabbe disease)
Mouse Galactocerebrosidase Unilateral ICV injection Enzyme detected in parenchyma. Subcellular staining
pattern consistent with a lysosomal/endosomal
distribution. Lifespan increased by about 20%.
Stroobants et al.,
2011
Metachromatic
leukodystrophy
Mouse Arylsulfatase A Unilateral ICV continuous
infusion
Enzyme detected in parenchyma co-localized with
neuronal cell markers and lysosomal markers. Signiﬁcant
reduction in storage material. Normalization of motor
incoordination and reduced gait homogeny in gait
analysis.
Tsuji et al., 2011 Tay-Sachs disease and
Sandhoff disease
Mouse β-hexosaminidase with a
high mannose 6-
phosphate-
type-N-glycan content
Bilateral ICV injection Enzyme detected in parenchyma, co-localized with
neuronal cell markers. Signiﬁcant reductions in storage
materials in neural cells. Delay in onset of motor
dysfunction as well as a 12% increase in lifespan.
Chang et al., 2008 Late infantile neuronal
ceroid lipofuscinosis
Mouse Tripeptidyl peptidase 1
proenzyme
Unilateral ICV continuous
infusion
Enzyme detected in parenchyma. Improvements inmean
tremor amplitude.
Xu et al., 2011 Late infantile neuronal
ceroid lipofuscinosis
Mouse Recombinant tripeptidyl
peptidase 1
IT via lumbar puncture Decline in gait analysis signiﬁcantly delayed. Lifespan
increased by about 30% to 40%.
Belichenko et al.,
2005
MPS I Rat α-L-iduronidase Unilateral ICV injection Enzyme detected in parenchyma.
Calias et al., 2012 MPS II Mouse Iduronate-2-sulfatase IT via lumbar puncture Enzyme detected in parenchyma. Reduction in storage
inclusions in neurons in gray matter and vacuolation
in oligodendrocytes in white matter.
Higuchi et al.,
2012
MPS II Mouse Iduronate-2-sulfatase Unilateral ICV injection Normalization of alternation behavior and arm entry in
Y-maze test.
Hemsley, 2007 MPS IIIA Mouse Heparan N-sulfatase Cerebellomedullary
cistern
injection
Reduction in storage material level throughout brain.
Reduction in storage vesicles in neuronal and glial cells
in cerebellum, cerebral cortex, and spinal cord.
Slower decline on open-ﬁeld testing over time.
Normalization of gait.
Hemsley et al.,, 2008 MSP IIIA Mouse Heparan N-sulfatase Cerebellomedullary
cistern
injection
Reduction in storage material level throughout brain.
Reduction in markers of brain inﬂammation.
Dodge et al., 2009 Niemann–Pick A Mouse Acid sphingomyelinase Unilateral ICV infusion Enzyme detected in parenchyma. Reductions in storage
material throughout brain. Improved performance on
foot
fault test. Improved gait analysis parameters.
Ziegler et al., 2011 Niemann–Pick A Rat Acid sphingomyelinase Unilateral ICV infusion Enzyme detected in parenchyma.
Abbreviations: GAG, glycosaminoglycan; HNS, heparan N-sulfatase; I2S, iduronate-2-sulfatase; IDU, α-L-iduronidase; MPS, mucopolysaccharidosis.
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lipofuscinosis, and Niemann-Pick A disease (Table 2). After IT or cisterna
magna administration, recombinant enzymes reached the hippocampus,
basal ganglia, thalamus, caudate, and periventricular white matter of
these large animals (Kakkis et al., 2004; Dickson et al., 2007; Hemsley
et al., 2009; Dierenfeld et al., 2010; Chen et al., 2011; Crawley et al.,
2011; Vuillemenot et al., 2011; Calias et al., 2012; Dickson et al., 2012).
Penetrationwas dose dependent, and regions of the brain that are closest
to the CSF surface accumulated the highest enzyme levels. Detectable
enzymatic activity in various CNS cell types and improvements in neuro-
pathology have been reported in some of the large animal studies
(Kakkis et al., 2004; Dickson et al., 2007; Hemsley et al., 2009; Chen
et al., 2011; Crawley et al., 2011; Vuillemenot et al., 2011; Calias et al.,
2012;Dickson et al., 2012; Pfeifer et al., 2012). For example, enzymatic ac-
tivity was detected in neurons and glia in all six neuronal layers of the ce-
rebral cortex and in white matter oligodendrocytes in non-human
primates and beagles that received lumbar IT or ICV doses of iduronate-
2-sulfatase (the enzyme that is deﬁcient in mucopolysaccharidosis II)
(Calias et al., 2012). Similarly, weekly intrathecal administration of re-
combinant human α-L-iduronidase to mucopolysaccharidosis I model
dogs revealed 2- to 5-fold elevated levels of enzyme in brain specimens
(Kakkis et al., 2004). Levels of pathologic glycosaminoglycan storage ma-
terial were normalized in the brains of these treated dogs, and neuronal
glycosaminoglycan storage was signiﬁcantly reduced as seen on electron
microscopy. Although improvement in cognitive function and memory
has been suggested by murine studies (Table 1), only one study included
testing for cognitive improvement in a large animal model of lysosomalstorage disease; that study had a sample size of one treated animal
which developed an immune response to the administered protein, and
no improvement or stabilization of cognitive function was seen
(Vuillemenot et al., 2011).
Investigational use of IT treatment in a human patient has been
reported in a case study of a male patient with mucopolysaccharidosis
I-Scheie (Munoz-Rojas et al., 2008). At the age of 38 years, the patient,
while presenting with near-normal intellectual function, developed
unstable and progressive spinal cord compression with resulting gait
ataxia and lower extremity numbness, tingling, and pain. The patient
refused standard surgical treatment. He was treated with IT injections
of laronidase (Aldurazyme®, BioMarin Pharmaceutical/Genzyme
Corporation, Cambridge, Massachusetts) via lumbar puncture at 1-
month intervals for a total of 4 months. After 6 months, his 12-minute
walk test distance increased by 14%, pulmonary function parameters
improved between 18% and 56%, a consistent right ankle clonus disap-
peared, and temperature sensation in the feet showed improvement.
Spinal canal stenosis remained stable on MRI. The patient reported
decreased numbness and tingling, increased stability when rising from
a chair and when walking, and decreased need for pain medication.
There was a reduction of 22.5% in CSF levels of glycosaminoglycan sub-
strate from baseline such that by month 4, the levels were normal.
Lysosomal enzymes may be particularly well suited for IT or ICV
delivery, as several viral vector studies have supported the idea that
lysosomal enzymes may undergo axonal transport, being transported
to and from a neuron cell body along microtubules through the cyto-
plasm of axons. A similar transport throughout the brain may occur
Table 2
Studies of IT administration of recombinant enzymes in large animals.
Study Disease Organism Protein Delivery Findings in Treated Animals Tolerability in Treated Animals
Kakkis et al.,
2004
MPS I Dog IDU IT injection weekly for
4 weeks
IDU levels increased 2.7 to 5.9-fold normal
levels depending on dose. Brain GAG levels
normalized. Neuronal GAG storage
signiﬁcantly reduced.
Well tolerated. All treated dogs developed
variable accumulations of immune cells in
meninges of spinal cord, areas of spinal dura,
and around brain. No clinical effects observed.
Dickson et al.,
2007
MPS I Dog IDU IT injection either
once monthly or
once every 3 months
IDU widely distributed throughout
brain tissue. Brain GAG levels normalized.
Neuronal GAG storage moderately reduced.
One dog in monthly group with baseline gait
disturbances improved on therapy.
Well tolerated. One dog in monthly group
developed a moderate neutrophilic meningitis.
One dog died from a large brain stem hematoma
caused by a traumatic injection.
Felice et al.,
2011
MPS II Cynomolgus
monkey
I2S IT injection monthly
for 6 months
I2S staining was observed both in surface
neurons next to meninges and in neurons
adjacent to white matter in a dose-dependent
manner.
Well tolerated. Leukocyte inﬁltrates observed in
meninges of brain in treated and control groups
without notable tissue damage. Anti-idursulfase
antibodies detected in two-thirds of treated
animals.
Calias et al.,
2012
MPS II Cynomolgus
monkey
I2S IT injection monthly
for 6 months
I2S detected in neurons of cerebrum,
cerebellum, brainstem, and spinal cord of
all groups in a dose-dependent manner.
Enzyme was speciﬁcally detected within
lysosomes of oligodendrocytes and neurons.
Not reported.
Calias et al.,
2012
MPS II Dog I2S Single IT injection I2S detected in all 6 neuronal layers of cerebral
cortex, as well as the cerebellar cortex,
hippocampus, thalamus, and caudate nucleus.
Not reported.
Hemsley
et al.,
2009
MPS III Dog HNS IT injection weekly
for up to
4 weeks
Increased HNS activity detected in the dorsal,
lateral and ventral cortical regions of cerebral
cortex. Reductions in GAG-derived
oligosaccharides were found in cerebellum
and in surface samples from brainstem,
spinal cord, and dura.
Well tolerated. One treated dog euthanized
because of development of a non-infectious
meningitis. All treated dogs developed antibodies
against HNS, and levels increased over time.
Pfeifer et al.,
2012
MPS III Juvenile
cynomolgus
monkeys
HNS IT injection every other
week for 6 months
Elevated HNS activity seen in surface as
well as periventricular areas of brain in
treated animals. HNS immunostaining seen
in meningeal and perivascular macrophages
of brain and spinal cord, in adjacent glial
and neuronal cell populations, and in
cerebellum.
Well tolerated. One female had to be sacriﬁced
early due to leaking device. All monkeys tested
positive for anti-HNS antibodies in serum and
CSF at one or more time points. Eosinophilic
inﬁltrates were present in brain and spinal cord
of some animals but did not causemorphological
changes.
Abbreviations: CSF, cerebrospinal ﬂuid; GAG, glycosaminoglycan; HNS, heparan N-sulfatase; I2S, iduronate-2-sulfatase; IDU, α-L-iduronidase; MPS, mucopolysaccharidosis.
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viral vectors that transduce cells only at the site of injection, but showed
detectable levels of enzyme activity and some correction of storage in
distal sites, including the contralateral hemisphere (Skorupa et al.,
1999; Bosch et al., 2000; Consiglio et al., 2001; Passini et al., 2002).
Passini et al. directly tested the axonal transport hypothesis by injection
of a viral vector expressing beta-glucuronidase, a lysosomal enzyme
that can be visualized in tissue sections, into mouse brain structures
that have deﬁned axonal connections to other structures (Passini
et al., 2002). The authors found that after injection of the vector unilat-
erally into the hippocampus of beta-glucuronidase–deﬁcientmice, gene
expression was detected only at the site of injection, but cells were
strongly positive for beta-glucuronidase activity in both hemispheres
of the hippocampus and in the septum. Only regions with axonal
connections to the site of transduction were enzyme positive. Storage
lesions in the distal structures were also reversed, suggesting that the
enzyme was correctly targeted to the lysosomal compartment and
remained enzymatically active after transport.
IT and ICV treatmentwith recombinant human enzymes not surpris-
ingly can be associatedwith an inﬂammatory response. As noted above,
this may be related to the reabsorption of CSF by way of routes previ-
ously discussed (Cserr & Knopf, 1992; Knopf et al., 1995). Homozygous
null animals, such as the mucopolysaccharidosis I canine model, show
variable accumulations of B lymphocytes, plasma cells, and other lym-
phocytes in the meninges of the spinal cord, areas of the spinal dura,
and around the brain (Kakkis et al., 2004). The inﬂammatory cells in
the meninges appeared more prominent in animals that were treated
with frequent doses or that developed immunoglobulin G antibodiesagainst the human protein (Dickson et al., 2007). Speciﬁc antibodies
were found in serum and CSF in these animals, and in dogs, cats
and monkeys receiving intra-CSF doses of other recombinant human
enzymes (Kakkis et al., 2004; Dickson et al., 2007; Hemsley et al.,
2009; Crawley et al., 2011; Felice et al., 2011; Vuillemenot et al., 2011;
Dickson et al., 2012; Pfeifer et al., 2012). Antibody formation may be
partly due to cross-species reactivity; however, titers in wild-type
animalswere lower than those seen innull animalmodels (Vuillemenot
et al., 2011). While in some cases the appearance of antibodies in the
serumandCSF coincidedwith thedevelopmentof infusion-related reac-
tions (Hemsley et al., 2009; Vuillemenot et al., 2011), the majority of
studies reported that no adverse effects were observed (Kakkis et al.,
2004;Dicksonet al., 2007;Crawley et al., 2011; Felice et al., 2011;Ziegler
etal.,2011;Dicksonetal., 2012;Pfeiferetal., 2012). Inthefuture,blocking
antibodyproductionbyinducingimmunetolerance(Dicksonetal.,2012)
or by neonatal exposure to the enzymes (Vogler et al., 1999; Dierenfeld
et al., 2010; Crawley et al., 2011)might enhance the effectiveness of IT
delivery of protein therapeutics.
4.3. IT Trastuzumab for breast cancer brain metastases
About 5% to 6% of patients with breast cancer develop brain metas-
tases (Schouten et al., 2002; Schouten et al., 2002; Barnholtz-Sloan
et al., 2004) at which point survival is about 7 months (Altundag
et al., 2007). In about 40% of patients with CNS metastases, the tumors
are positive for human epidermal growth factor receptor 2 (HER-2)
(Altundag et al., 2007). Trastuzumab, a humanized anti–HER-2 mono-
clonal antibody, has been shown in several large, prospective, controlled
Table 3
Case reports of IT delivery of trastuzumab in patients with MC from breast cancer.
Report Patient Treatment Outcome
Laufman and
Forsthoefel, 2001
48-year-old female with mid-back
pain and sudden paralysis
3 IT doses of trastuzumab escalating from
5 to 20 mg over 2 weeks.
Treatment well tolerated.
Concomitant treatment with IT thiotepa
and/or methotrexate.
No beneﬁts seen after ﬁrst 2 doses. After third dose,
patient remained neurologically stable for 30 days,
then declined and died of respiratory arrest.
Stemmler et al.,
2006
39-year-old female with dizziness,
hearing loss, and headache.
4 IT doses of trastuzumab escalating from
5 to 20 mgover 2 weeks followed by another
20 mg dose 3 weeks later.
Treatment well tolerated.
Neurological symptoms improved within 2 weeks
from last dose.
Concomitant treatment with IV trastuzumab
and chemotherapy every 3 weeks continued.
Tumor cell count in CSF remained low for 11 months
from ﬁrst diagnosis of MC.
Progression of MC occurred after 11 months.
Platini et al., 2006 41-year-old female with vertigo,
memory and sleep problems, and
difﬁculty concentrating.
IT trastuzumab escalating from 20 mg to
25 mg given weekly for about 1 year.
Treatment well tolerated.
IT 25 mg prednisone and 10 mg thiotepa
added after 1 year. Total of 46 IT injections
over 17 months. Concomitant treatment
with IV
trastuzumab and chemotherapy continued.
Patient developed vision disturbances after 1 year of
IT trastuzumab. These stabilized after addition of
prednisone and thiotepa. Progression was again seen
6 months later with nausea, vomiting, and exacerba-
tion
of vision problems.
Stemmler et al.,
2008
48-year-old female with overﬂow
incontinence and paraparesis of the legs.
4 IT doses 12 mg methotrexate and
20 mg trastuzumab.
Treatment well tolerated.
Tumor cell count in CSF decreased within 2 weeks.
Patient’s general condition improved signiﬁcantly
(Eastern Cooperative Oncology Group 3 to 1) and she
was able to walk again without assistance.
Tumor cell count was negative by the end of
treatment.
After 1 month, patient died due to rapid progression of
lung and liver metastases, with no signs of MC.
Mir et al., 2008 59-year-old female with mid-back
pain, cerebellar ataxia and headaches.
6 IT doses of trastuzumab escalating from
20 to 100 mg given weekly.
Treatment well tolerated.
MRI at 6 weeks showed stable MC.
2 months later patient died of rapidly progressing
brain
metastasis to parenchyma.
Ferrario et al, 2009 38-year-old female with visual impairment,
right ptosis, right hemi-facial hypoesthesia,
left foot drop, and paralysis of the left facial
nerve.
6 IT doses of trastuzumab given weekly,
escalating from 20 to 30 mg, followed by
Treatment well tolerated.
2 IT doses of 30 mg trastuzumab plus
10 mg methotrexate given weekly.
MRI revealed that all the lesions were stable or slightly
decreased after 40 mg trastuzumab plus 10 mg
thiotepa.
IT doses of 40 mg trastuzumab given
every 3 weeks for 8 months.
Signiﬁcant improvement, with some lesions
signiﬁcantly decreasing in size, and other lesions no
longer visualized, seen after 50 mg trastuzumab plus
12 mg thiotepa.
IT doses of 40 mg trastuzumab plus 10 mg
thiotepa given every 3 weeks for
6 months. Patient was fully functional at end of treatment.
IT doses of 50 mg trastuzumab plus 12 mg
thiotepa given every 3 weeks for 7 months.
Concomitant treatment with IV
chemotherapy every 3 weeks continued.
Mego et al., 2011 43-year-old female with dizziness and
cranial nerve palsies.
6 IT doses of 15 mg methotrexate,
24 mg cytarabine, and 24 mg
hydrocortisone plus escalating dose
of trastuzumab up to 40 mg given
weekly. Systemic trastuzumab continued.
Treatment well tolerated.
CSF protein level remained elevated but CSF tumor
cell counts were negative.
Symptoms improved signiﬁcantly.
2 months later presented with impaired level of
consciousness but refused further treatment.
Overall survival was 13.5 months from diagnosis of
MC.
Mego et al., 2011 39-year-old female with vision disorders,
headaches, dizziness, cranial nerve palsies,
and sleepiness.
6 IT doses of 15 mg methotrexate, 24 mg
cytarabine, and 24 mg hydrocortisone plus
escalating dose of trastuzumab up to
100 mg given weekly.
Treatment well tolerated
Tumor cell count in CSF decreased, then was negative
by last infusion.
Symptoms improved signiﬁcantly.
Lesions were reduced on MRI.
6 months after last IT infusion, died due to progression
of liver metastases, free of symptoms of MC.
Oliveira et al., 2011 44-year-old female with headache, gait
disturbance, neck stiffness, and reduced
ﬂexion of lower limbs.
67 weekly IT doses of 25 mg trastuzumab
plus 25 mg prednisolone.
Treatment well tolerated.
Systemic trastuzumab plus chemotherapy
continued.
After 3 doses, recovered lower limb motion and
resumed daily physical activities.
Tumor cell count in CSF was negative after third dose
and thereafter.
The patient died from Listeriameningitis 27 months
after diagnosis of MC. No evidence of MC was seen on
autopsy.
Brandt, 2012 49-year-old female with headache, mental
status changes, seizures, and lower limb
weakness.
IT doses of 25 mg trastuzumab given every
other day for 3 weeks, followed by doses
given weekly for 43 months, followed by
doses given biweekly to present time.
Systemic trastuzumab plus capecitabine
and lapatinib continued.
Treatment well tolerated.
Improvement in mental status after 2 doses.
After 3 months, all neurological compromises abated
and have remained so to date.
Abbreviations: CSF, cerebrospinal ﬂuid; IT, intrathecal; IV, intravenous; MC, meningeal carcinomatosis; MRI, magnetic resonance imaging.
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HER-2–positive breast cancer (Slamon et al., 2001; Smith et al., 2007)
and is used as part of the ﬁrst-line treatment regimens in these pop-
ulations. Unfortunately, peripherally administered trastuzumab
does not reach therapeutic levels in the brain because of poor pene-
tration of the BBB (Stemmler et al., 2007). A number of case reports
documenting the use of IT delivery of trastuzumab in patients with
leptomeningeal carcinomatosis have suggested that this route of ad-
ministration is well tolerated (Table 3). IT trastuzumab improved
clinical status and neurological complaints, and the overall survival
appeared to be greater than what would be expected in this patient
population. The safety of IT trastuzumab was evaluated in a formal toxi-
cology study performed in cynomolgus monkeys. Animals received
weekly IT trastuzumab at doses of 0, 3, or 15 mg for four weeks, and no
drug-related effects on body weight, clinical signs, neurological function,
clinical pathology, or anatomic pathology were seen, even at CSF
concentrations that exceeded those reported in patients in the IT
case studies (Braen et al., 2010). Phase I/II trials in human patients
with leptomeningeal carcinomatosis are in progress (NCT01373710,
NCT01281696, NCT01645839, NCT01325207).5. Drugs delivered by the intrathecal
route: Characteristics of the ideal molecule
The studies reviewed here illustrate that, contrary to traditional
dogma, some molecules administered by the IT route can exert thera-
peutic effects on the CNS. The traditional view was based on and is
largely true for small, lipid-soluble molecules. The molecules that are
able to reach the CNS in therapeutic amounts after IT delivery tend to
share a number of characteristics. Ideal molecules are usually proteins
with little or no brain-to-blood passage at the level of the blood–brain
barriers and are relatively resistant to degradation by the enzymes
found within the CSF. Although the CSF has been shown to contain
hundreds of proteins (Bora et al., 2012; Holtta et al., 2012) and may
have a lower enzymatic activity than blood, enzymatic susceptibility
should be evaluated for each drug candidate individually during the de-
velopment process. Distribution to deep brain tissues after IT delivery
can also be aided by receptormediated cellular uptake and intercellular
transfer. The lysosomal enzymes, for which some success in IT delivery
has been reported, are examples of protein drugs with these character-
istics. Without such intracellular and intercellular distributions, another
characteristic of the ideal molecule would be a site of action within
diffusible distance of a CSF-contacting area or accessed by the deep
subarachnoid circulation recently described by Iliff and colleagues (Iliff
et al., 2012). Another advantage of IT delivery of a protein therapeutic
with a high therapeutic index is that the drug may be able to treat not
only the neurological but also the peripheral symptoms of the disease.
Inmost cases, CNSdelivery results in the drug entering the blood stream
as the CSF is reabsorbed.
There are also several disadvantages of IT delivery of therapeutic
proteins. One is the development of antibodies that tend to reduce the
effectiveness of the drugs. Another is that it may be difﬁcult to predict
the percent of an IT dose of a drug that will reach the brain and cranial
CSF space; this may be caused by the variations in rates of CSF and
metabolic free water production and reabsorption. Chronic IT delivery
would be easier to achieve with the placement of indwelling catheters
rather than repeated lumbar punctures; however, treatment would
then be dependent on reliable catheter placement and stability. Some
disease conditions may complicate catheter placement or stability,
such as obesity or rapid growth rates in children (Follett et al., 2003).
Infection is a risk that must be managed as well, with rates of infection
with implanted IT catheters reported to be between 4% and 9% (Du Pen,
2005; Holmfred et al., 2006; Aprili et al., 2009; Taira et al., 2013;Motta &
Antonello, 2014). Thus, even in the best of circumstances, catheters
require periodic replacement.6. Conclusions
Whereas early experiences with small, lipid-soluble molecules
resulted in the IT route for drug administration being discounted, new
evidence demonstrates that IT delivery may be an ideal route of admin-
istration for large biomolecules. Numerous studies in small and large
animal models of stroke and the neurodegenerative lysosomal storage
diseases show that IT delivery of protein therapeutics can result in
widespread penetration into the brain parenchyma, improved signs of
neuropathology, and improved clinical and behavioral outcomes.
Tolerability to treatment was generally good in these studies.
Similarly, case reports and studies in human patients with a neu-
rodegenerative lysosomal storage disease or breast cancer metas-
tases to the CNS have suggested generally acceptable tolerability
and therapeutic effectiveness with few adverse events after the IT
delivery of enzymes or antibodies. A number of clinical trials of
IT-administered protein therapeutics are underway for patients
with mucopolysaccharidosis I (NCT00638547, NCT00852358),
mucopolysaccharidosis II (NCT00920647, NCT01506141) and
mucopolysaccharidosis III (NCT01155778, NCT01299727);
leptomeningeal carcinomatosis (NCT01373710, NCT01281696,
NCT01645839, NCT01325207) and intraventricular hemorrhage
(NCT01810302). It is anticipated that results from these trials will
help guide clinical implementation of IT drug delivery on a larger
scale and will inform therapeutic efforts for a variety of neurological
disorders.
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